RPG Life Sciences Share Price

    NSE
    2487.4
    +86.40 (3.52%)
    RPGLIFE • 30 Jun, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    49.09%

    3Y Annualised Return

    62.87%

    5Y Annualised Return

    55.31%

    The current prices are delayed, login or Open Demat Account for live prices.

    RPG Life Sciences Stock Performance

    1W Return2.77
    1Y Return51.06
    Today's Low2411.8
    Prev. Close2,401.00
    Mkt Cap (Cr.)4,103.00
    1M Return13.74
    3Y Return342.80
    52-Week High2974.95
    Open2,411.80
    PE Ratio35.50
    6M Return18.92
    Today's High2490
    52-Week Low1539.95
    Face Value8

    RPG Life Sciences Company background

    Founded in: 2007
    Managing director: ASHOK NAIR
    RPG Life Sciences Limited, formerly known as Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).RPG Life Sciences Limited was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Limited . During the year 200708, as per the Scheme of Arrangement, the Company acquired the Pharmaceuticals Business of Brabourne Enterprises Limited along with all assets and liabilities pertaining to that business with effect from April 2, 2007. On February 13, 2008, the name of the Company was changed to RPG Life Sciences Limited.During the year 200809, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, QugylO Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 200910, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, antiulcerant, antidepressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments.The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 200910. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, antiulcerant, antidepressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010.New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neolife). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 201011. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 201617. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 201617.In 201718, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the posttransplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY18. It retained leadership position in Mauritius, through antidiabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space.During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, TJAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and AldactoneF was launched in FY 2022.In 2024, the Company launched a digital platform for comprehensive doctor engagement, RPGserv, which integrates physical and digital capabilities. The Companys portfolio has been strengthened by new launches in Cardiovascular, Diabetology, Nephrology, Rheumatology, Oncology and Urology segments and by entering clinical Dermatology, Orthopedic and Critical Care segments in FY2425.

    As of 30 Jun, 2025, RPG Life Sciences share price is ₹2480.8. The stock opened at ₹2411.8 and had closed at ₹2401 the previous day. During today’s trading session, RPG Life Sciences share price moved between ₹2,411.80 and ₹2,490.00, with an average price for the day of ₹2450.90. Over the last 52 weeks, the stock has recorded a low of ₹1,539.95 and a high of ₹2,974.95. In terms of performance, RPG Life Sciences share price has increased by 17% over the past six months and has increased by 49.09% over the last year.

    Read More
    RPG Life Sciences SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹83,97,766 (+29.20%)

    Daily SIP of 25,000 would have become 83,97,766 in 1 year with a gain of 18,97,766 (+29.20%)

    View details of Market Depth

    RPG Life Sciences Fundamental

    Market Cap (in crs)

    4,103.00

    Face Value

    8

    Turnover (in lacs)

    764.04

    Key Metrics

    Qtr Change %
    61.10% Gain from 52W Low
    8.7
    Dividend yield 1yr %
    Below industry Median
    1

    Top Mutual Fund Invested in RPG Life Sciences

    Promoter
    73%
    Foreign Institutions
    1.5%
    Mutual Funds
    3.5%
    Domestic Institutions
    6.1%
    Public
    19.5%
    Promoter
    73%
    Foreign Institutions
    1.3%
    Mutual Funds
    3.5%
    Domestic Institutions
    6.1%
    Public
    19.7%
    Promoter
    72.8%
    Foreign Institutions
    1.4%
    Mutual Funds
    2.7%
    Domestic Institutions
    5.4%
    Public
    20.4%
    Promoter
    72.8%
    Foreign Institutions
    1.2%
    Mutual Funds
    1.6%
    Domestic Institutions
    4.6%
    Public
    21.4%
    Promoter
    72.8%
    Foreign Institutions
    0.9%
    Mutual Funds
    1.5%
    Domestic Institutions
    4.2%
    Public
    22.1%
    Promoter
    72.8%
    Foreign Institutions
    0.6%
    Mutual Funds
    1.1%
    Domestic Institutions
    3.8%
    Public
    22.8%

    RPG Life Sciences Technical Analysis

    Moving Averages Analysis
    2487.4
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    2,432.30
    10Day EMA
    2,396.60
    12Day EMA
    2,382.60
    20Day EMA
    2,335.60
    26Day EMA
    2,309.90
    50Day EMA
    2,257.50
    100Day EMA
    2,229.30
    200Day EMA
    2,161.30
    5Day SMA
    2,431.40
    10Day SMA
    2,398.90
    20Day SMA
    2,308.20
    30Day SMA
    2,261.10
    50Day SMA
    2,213.10
    100Day SMA
    2,227.20
    150Day SMA
    2,215.20
    200Day SMA
    2,273.70
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    14775 Rs
    32139 Rs
    Week Rs
    9131 Rs
    19699 Rs
    Month Rs
    12000 Rs
    34614 Rs
    2,460.87
    Pivot
    Resistance
    First Resistance
    2,509.93
    Second Resistance
    2,539.07
    Third Resistance
    2,588.13
    Support
    First Support
    2,431.73
    Second support
    2,382.67
    Third Support
    2,353.53
    Relative Strength Index
    66.33
    Money Flow Index
    79.98
    MACD
    72.72
    MACD Signal
    60.38
    Average True Range
    91.72
    Average Directional Index
    31.32
    Rate of Change (21)
    13.74
    Rate of Change (125)
    17.04
    Name
    Holding Percent
    Quant Mutual Fund - Quant Active Fund
    1.98
    Mirae Asset Multicap Fund
    1.12
    Authum Investment And Infrastructure Limited
    2.02

    RPG Life Sciences Latest News

    25 JUN 2025 | Wednesday

    RPG Life Sciences Ltd - 532983 - Closure of Trading Window

    24 JUN 2025 | Tuesday

    RPG Life Sciences Ltd - 532983 - Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company

    24 JUN 2025 | Tuesday

    RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    View More

    RPG Life Sciences Share Price FAQs

    RPG Life Sciences share price is ₹2487.4 in NSE and ₹2480.45 in BSE as on 30/6/2025.

    RPG Life Sciences share price in the past 1-year return was 51.06. The RPG Life Sciences share hit a 1-year low of Rs. 1539.95 and a 1-year high of Rs. 2974.95.

    The market cap of RPG Life Sciences is Rs. 4103 Cr. as of 30/6/2025.

    The PE ratios of RPG Life Sciences is 35.5 as of 30/6/2025.

    The PB ratios of RPG Life Sciences is 7.73 as of 30/6/2025

    The Mutual Fund Shareholding in RPG Life Sciences was 3.53% at the end of 30/6/2025.

    You can easily buy RPG Life Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of RPG Life Sciences share price is ₹2974.95 and ₹1539.95 as of 30/6/2025.

    Please be aware that RPG Life Sciences stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    820.35
    +14.95 (+1.86%)
    1,500.60
    -14.80 (-0.98%)
    2,001.50
    -13.40 (-0.67%)
    1,601.80
    -6.20 (-0.39%)
    3,462.00
    +20.90 (+0.61%)
    Top Gainers
    6,217.50
    +198.00 (+3.29%)
    820.35
    +14.95 (+1.86%)
    421.50
    +7.00 (+1.69%)
    872.10
    +14.40 (+1.68%)
    326.75
    +3.30 (+1.02%)
    Top Losers
    1,098.90
    -25.40 (-2.26%)
    1,199.20
    -25.90 (-2.11%)
    2,163.50
    -44.40 (-2.01%)
    4,237.10
    -83.20 (-1.93%)
    12,400.00
    -242.00 (-1.91%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -